Key result
LOX overexpression was identified as a prognostic factor for poor progression-free survival and was associated with chemotherapeutic resistance in patients with ER- breast cancer.
Observational
LOX overexpression in ER- breast cancer is associated with poor progression-free survival and specific chemoresistance profiles, suggesting potential targeted therapeutic strategies.
LOX may aid resistance prediction in ER- breast cancer; leaves open whether targeting LOX alters outcomes.
// Yong Han 1, * , Shenyi Lian 2, * , Xingran Cui 3 , Kexin Meng 4 , Balázs Győrffy 5, 6 , Tao Jin 7 , Dongsheng Huang 1 1 Clinical Research Institute, Zhejiang Provincial People’s Hospital, Hangzhou, China 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, China 3 Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA 4 Department of Thyroid Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China 5 Momentum Cancer Biomarker Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary 6 Second Department of Pediatrics, Semmelweis University, Budapest, Hungary 7 Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China * These authors contributed equally to this work Correspondence to: Tao Jin, email: onlune@126.com Dongsheng Huang, email: dshuangzry@gmail.com Keywords: LOX, estrogen recepter, EMT, chemoresistance, bisphosphonates Received: September 01, 2015 Accepted: April 11, 2016 Published: April 28, 2016 ABSTRACT Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER–) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER– breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER– patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER– breast cancer patients, experiments to validate the function of LOX in ER– breast cancer are still needed.
No takes yet. Share an insight, caveat, or question.
Han et al. (2016) conducted an observational in Estrogen receptor negative (ER-) breast cancer. LOX overexpression was evaluated on Progression free survival. LOX overexpression was identified as a prognostic factor for poor progression-free survival and was associated with chemotherapeutic resistance in patients with ER- breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: